DiscGenics Revenue and Competitors

Claim your profile

Location

$68M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DiscGenics's estimated annual revenue is currently $6M per year.(i)
  • DiscGenics's estimated revenue per employee is $155,000
  • DiscGenics's total funding is $68M.

Employee Data

  • DiscGenics has 39 Employees.(i)
  • DiscGenics grew their employee count by -5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7480.2M197895%N/AN/A

DiscGenics is a privately held, clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenicsᅢᄁ¬ツᆲ¬トᄁ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

keywords:N/A

$68M

Total Funding

39

Number of Employees

$6M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DiscGenics News

2022-03-30 - Spinal News International's top 10 most popular stories of ...

Positive interim data that highlighted the safety and efficacy of DiscGenics' cell therapy for degenerative disc disease was the most-read...

2020-09-09 - DiscGenics Appoints Former Medtronic Spine and Biologics Finance Executive as First Chief Financial Officer

SALT LAKE CITY, Sept. 9, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has appointed former Medtroni ...

2020-08-27 - DiscGenics Raises $50M in Series C Funding

DiscGenics, Inc., a Salt Lake City, UT-based clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, raised $50m in Series C funding. The round was led by Ci:z Investment ...

2020-08-25 - DiscGenics Raises $50 Million in Series C Funding

SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has raised $50 million in a Ser ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M39875%$15.9M
#2
$4.1M39105%$9.6M
#3
$3.9M3977%$6.3M
#4
$8.4M39105%N/A
#5
$6.7M40-47%N/A